Skip to search formSkip to main contentSkip to account menu

CH 4987655

Known as: CH-4987655, CH4987655 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

BenzamidesOxazines

Narrower (1)

RO4987655

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
Purpose: This phase I study of the mitogen-activated protein/extracellular signal–regulated kinase inhibitor RO4987655 (CH4987655… 
2012
2012
Translational biomarker in oncology early clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Biomarkers of drug activity are increasingly important tools in oncology early drug development, particularly in this era of… 
Highly Cited
2011
Highly Cited
2011
Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent.
2009
2009
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker
Purpose: CH4987655 (RO4987655) is an orally active and highly selective small-molecule MEK inhibitor. It potently inhibits… 
2009
2009
Cancer Therapy : Clinical The Safety , Tolerability , Pharmacokinetics , and Pharmacodynamics of Single Oral Doses of CH 4987655 in Healthy Volunteers : Target Suppression Using a Biomarker
Purpose:CH4987655 (RO4987655) is an orally active and highly selective small-molecule MEK inhibitor. It potently inhibits mitogen… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)